The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (US, CA), Seretide (Australia, Colombia, EU, MÃÆÃâÃâÃÂ©xico, New Zealand, South Africa, South Korea, UK), Viani (Germany), Adoair (Japan), ForAir (India) and Foxair (South Africa).
Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination, while salmeterol treats constriction of the airways. Together, they relieve the symptoms of coughing, wheezing and shortness of breath.
H. O.-102, Sector-78, Sakatpur, Gurgaon, Haryana, 122002, India